SHAREHOLDER ALERT: WeissLaw LLP Investigates Diplomat Pharmacy, Inc.

NEW YORK, Dec. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE: DPLO) in connection with the proposed acquisition of the Company by UnitedHealth Group's (NYSE: UNH) OptumRx.  Under the terms of the acquisition agreement, DPLO shareholders will receive $4 per share in cash.

If you own DPLO shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://weisslawllp.com/diplomat-pharmacy-inc-investigation/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether Diplomat's Board acted to maximize shareholder value prior to entering into the acquisition agreement.  Notably, the deal represents a 31% discount from DPLO's closing price on Friday, the last day of trading before the deal was announced.  Additionally, the Company's "crown jewel" infusion business, as one analyst put it, operates in all 50 states and Washington D.C. 

Given these facts, WeissLaw is concerned whether the proposed acquisition agreement undervalues the Company, whether the Board ran a fair process, and whether all material information related to the proposed acquisition is fully and fairly disclosed. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected].

SOURCE WeissLaw LLP